Oral Lactobacillus Supplementation as Treatment for Overactive Bladder Syndrome: A Randomised Controlled Trial

Launched by MEDICAL UNIVERSITY OF VIENNA · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a possible new treatment for Overactive Bladder Syndrome (OAB), which is a condition that causes frequent urges to urinate and may lead to accidents. It can significantly impact the daily lives of those affected, especially older women, as it affects about 13% of them. The researchers want to find out if taking an oral supplement containing Lactobacillus, a type of beneficial bacteria, can help reduce these symptoms.

Women between the ages of 65 and 74 who have been diagnosed with OAB or mixed urinary incontinence may be eligible to participate. Participants will take either the Lactobacillus supplement or a placebo (a non-active pill) twice a day for six months. Throughout the study, researchers will check participants' symptoms and analyze samples to see how the treatment affects their urogenital microbiome—the community of bacteria in that area. This study is not yet recruiting participants, but it aims to provide more options for managing OAB if the treatment proves effective.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of overactive bladder syndrome or mixed urinary incontinence with predominance of overactive bladder symptoms
• Exclusion Criteria:
• • under age 18
• • neurogenic overactive bladder